Degradation dynamics of Trifluralin in Qinghai-Tibet Plateau and screening of its degrading strains.

Trifluralin (FLL) is extensively used in rapeseed fields in the Qinghai-Tibet Plateau (QTP) region. However, the degradation kinetics of FLL in this area and its impact on environmental microbial communities are not yet known. To investigate the degradation patterns and ecological benefits of FLL, this study established a comprehensive method for detecting FLL residues and selected efficient degrading bacterial strains.

Swift and portable detection of SC7 through RNA extraction and loop-mediated isothermal amplification using lateral flow device.

The soybean mosaic disease-caused by the (SMV)-significantly impacts soybean quality and yield. Among its various strains, SMV-SC7 is prevalent in China. Therefore, rapid and accurate diagnosis is deemed critical to mitigate the spread of SMV-SC7.

ABCoRT: Retention Time Prediction for Metabolite Identification via Atom-Bond Co-Learning.

Liquid chromatography retention time (RT) prediction plays a crucial role in metabolite identification, a challenging and essential task in untargeted metabolomics. Accurate molecular representation is vital for reliable RT prediction. To address this, we propose a novel molecular representation learning framework, ABCoRT(tom-ond -learning for etention ime prediction), designed for predicting metabolite retention times.

Efficacy and safety of SHR8554 on postoperative pain in subjects with moderate to severe acute pain following orthopedic surgery: A multicenter, randomized, double-blind, dose-explored, active-controlled, phase II/III clinical trial.

Biased µ-opioid receptor (MOR) agonists enhance pain relief by selectively activating G protein-coupled receptor signaling and minimizing β-arrestin-2 activation, resulting in fewer side effects. This multicenter Phase II/III trial evaluated the optimal dosage, efficacy, and safety of SHR8554, a biased MOR agonist, for postoperative pain management following orthopedic surgery. In Phase II, 121 patients were divided into four groups to receive varying patient-controlled analgesia (PCA) doses of SHR8554 or morphine.